If the iPSCs you would like to access are currently listed as unavailable or
you would like information on local partners in USA, Australia, New Zealand or Japan who can support order and delivery,
please get in touch via
Contact@EBiSC.org.
SIGi001-A-14
SIGi001-A Bi-Allelic MAPT HA-tag
Gene-edited iPSC line
A CLIP contains information about an iPSC line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the iPSC line.
The EBiSC Access and Use Agreement must be completed along with an individual
Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org
for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
iPSC Line |
|
| hPSCreg name | SIGi001-A-14 |
| Alternative name(s) |
SIGi001-A Bi-Allelic MAPT HA-tag
|
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines |
SIGi001-A-1 (iPSC0028 SLC17A7/GFP E3) SIGi001-A-2 (iPSC0028 SLC17A7/GFP C3) SIGi001-A-3 (iPSC0028 MAPT P301L C4) SIGi001-A-4 (iPSC0028 MAPT P301L D4) SIGi001-A-5 (iPSC0028 MAPT P301S 1C9C4) SIGi001-A-6 (iPSC0028 MAPT P301S 1B9C9) SIGi001-A-7 (iPSC0028 MAPT P301S 2G2B7) SIGi001-A-8 (iPSC0028 MAPT P301S+Ex10+16/Clone 7D11A7) SIGi001-A-9 (iPSC0028 MAPT P301S+Ex10+16/Clone 7H6A1) SIGi001-A-10 (iPSC0028 MAPT P301S+Ex10+16/Clone 7G4A8) SIGi001-A-11 (iPSC0028 MAPT P301S+Ex10+16/Clone 7C6A4, SAMEA4451118) SIGi001-A-12 (iPSC0028 - BiAllelic MAPT_Ex10+16T/Clone 1F5-D12, SAMEA104237570) SIGi001-A-13 (iPSC0028 – MonoAllelic MAPT_Ex10+16T/Clone 1D01-11) SIGi001-A-15 (SIGi001-A Dox inducible NGN2) SIGi001-A-16 (SIGi001-A-9 Bi-Allelic MAPT HA-tag) SIGi001-A-17 (SIGi001-A-9 Dox inducible NGN2) SIGi001-A-18 (SIGi001-A-12 Bi-Allelic MAPT HA-tag #U28-12-P29-5) SIGi001-A-19 (SIGi001-A-12 Dox inducible NGN2) |
| Notes | SIGi001-A having a HA-tag at the C-terminal end of MAPT, Bi-Allelic |
Provider |
|
| Depositor | Bioneer (BION) |
| Owner | Bioneer (BION) |
| Distributors |
EBiSC
|
| Derivation country | Denmark |
External iPSC Databases |
|
| hPSCreg | SIGi001-A-14 |
| BioSamples | SAMEA6080813 |
| Cellosaurus | CVCL_A7GS |
| Wikidata | Q107116924 |
General iPSC Information |
|
| This EBiSC iPSC line can be used for: |
Yes
Research use: allowed
Clinical use: no
Commercial use: no
|
| Subclone of | (not in EBiSC, see SIGi001-A in hPSCreg) |
iPSC Genetic Modification#
| Genetic modifications not related to a disease |
|
Donor Information#
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | no |
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA4447434 |
iPSC Derivation#
General |
|
|
More source cell information can be found in the parental cell line
SIGi001-A in hPSCreg.
|
|
| Passage number reprogrammed | 0 |
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Genes | |
| Is the used vector excisable? |
No |
| Absence of reprogramming vector(s)? |
No |
| Reprogramming vectors silenced? |
Unknown |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
iPSC Culture Conditions#
Latest released batch |
|
| Culture medium | mTeSR1 |
| Passage method | Accutase |
| Surface coating | Matrigel |
| O2 concentration | 21 |
| CO2 concentration | 5 |
| Temperature | 37 °C |
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
Accutase
|
| O2 Concentration | 5 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
iPSC Characterisation#
Analysis of undifferentiated iPSCs
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Morphology pictures
Stem cell marker and Tri-lineage differentiation by flow cytometry
Differentiation Potency
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
Sterility |
|
| Inoculation for microbiological growth | No Contaminants Detected |
| Mycoplasma | Not Detected |
| Viability | Viable post-cryopreservation |
Genotyping#
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
|
Other Genotyping (iPSC Line) |
|